Auto-injectors Market Players:
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Scandinavian Health Ltd.
- AbbVie, Inc.
- Amgen
- Owen Mumford
- Ypsomed
- Biogen Idec
- Mylan N.V.
- Pfizer, Inc.
- Sanofi
- Stevanato Group
- Teva Pharmaceutical
- Taisho Pharmaceutical Co., Ltd.
Key players in the market are currently focusing on gaining an optimum safety profile for their pipelines for seamless globalization and large-scale production. In this regard, in June 2024, Instron introduced the next-generation Autoinjector Testing System to ensure the product’s compliance with performance requirements and ISO 11608 criteria. Simultaneously, many pharmaceutical giants are adopting this method of administration to make their medicines more accessible and easier to use for consumers. For instance, in February 2025, Eli Lilly and Company availed extended doses and savings options of Zepbound for self-pay patients, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pen. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of auto-injectors is assessed at USD 11.81 billion.
The global auto-injectors market size surpassed USD 10.53 billion in 2025 and is projected to witness a CAGR of over 13.5%, crossing USD 37.36 billion revenue by 2035.
North America auto-injectors market is poised to capture 45% share by 2035, fueled by rising healthcare investment and biosimilar product launches.
Key players in the market include Scandinavian Health Ltd., AbbVie, Inc., Amgen, Owen Mumford, Ypsomed, Biogen Idec, Mylan N.V., Pfizer, Inc., Sanofi, and Stevanato Group.
